New Delhi: BramhAnsh Technologies, a startup based in Bengaluru, is leading the MedTech industry revolution with its innovative research-backed low-frequency sound wave technology that is bone-conducting and is capable of stimulating nerve activity. This approach, inspired by sound wave-based treatments, has yielded a clinically validated solution with treatment and preventive capabilities.
Back in 2015 when Jaideep Tiwari, Founder and CEO of BramhAnsh Technologies, was personally diagnosed with an anxiety disorder and required treatment. Rather than succumbing to this challenge, he, along with his friend K. Kartik, Co-founder and COO of the company decided to harness the potential of technology to address mental health issues. With a history of collaboration and shared interests dating back to college days, they embarked on a mission to establish a company that would leverage technology to provide relief from a wide range of disorders. As emerging young entrepreneurs hailing from a small town in Chhattisgarh, they carried a grand vision.
The company’s journey began officially in 2017 when it was incorporated and it actually initiated extensive research into the development of a technology that uses sound waves as a method of stimulation to calm down the nervous system.
“After countless hours of research, dedication, and hard work, we successfully developed the remarkable technology. In 2020, we received a patent for our innovation, which was proudly named Migraelief,” says Jaideep Tiwari, Founder and CEO of BramhAnsh Technologies.
“Our USP lies in our products, which distinguish themselves in the market due to their affordability and exceptional performance, compared to existing treatment methods. As a company, we maintain a persistent commitment to continuous innovation, with plans to introduce more groundbreaking technologies into the MedTech Industry. We are a leader in the MedTech industry because we strongly prioritize making our products affordable, easy to use, and of high quality. We are focusing on bringing positive changes and enhancing the overall healthcare experience,” Jaideep adds further.
Key milestones
-
2017 Research initiated to create a technology utilizing sound waves for nervous system stimulation.
-
2018 Company officially incorporated, marking the beginning of two intensive years focused on technology development.
-
2020 The granting of patent, the development of a Minimum Viable Product (MVP), and the successful completion of over 500 human trials.
-
2022 Regulatory clearances, including CE, ISO 13485, and CDSCO approvals. Preparations for conducting clinical trials initiated.
-
2023 Clinical trials & comprehensive market research commenced, and successful launch of the product.
Addressing the elusive migrane problem
Migraelief, the first wearable device for migraine treatment in India is a medical-grade device that has been clinically validated and developed to assist individuals who have not found relief for their migraine symptoms through other treatments.
Migraelief is a CDSCO-registered and ISO-CE-certified device that utilizes research-backed low-frequency sound waves that can conduct through bone which is generated by the developed patented transducer technology. It has a unique band design and transducer placement that enables the efficient distribution of low-frequency waves across the head and ensures efficient neuromodulation by stimulating the nerves. It ensures non-invasive and medication-free relief, which is particularly beneficial for individuals who experience limitations or side effects with medications.
“We aim to lead the MedTech industry revolution with innovative research-backed low-frequency sound wave technology that is bone-conducting and is capable of stimulating nerve activity.”
Jaideep Tiwari, Founder and CEO, BramhAnsh Technologies
Migraelief stands at the forefront of global innovation in sound wave-based migraine treatment, with an outstanding success rate of 82%. The Migraelief device is designed to be worn as a headband, strategically positioned at the center of the forehead. This innovative approach to migraine management offers a swift and effective solution, capable of alleviating acute migraine pain within a mere 20 minutes. Furthermore, Migraelief extends its utility beyond immediate relief, making it suitable for preventive treatment.
The Migraelief App empowers users to personalize their treatment, track symptoms, and facilitate better migraine management through shared records with healthcare professionals. Notably, Migraelief significantly reduces work-related impairments and the need for medication. It extends its benefits proactively, curbing the frequency and intensity of migraines. Clinical Trial Reports firmly support these advantages, underscoring Migraelief’s life-changing impact on enhancing the quality of life for migraine sufferers worldwide.
Major focus on R&D with novel product pipeline
BramhAnsh Technologies allocates a substantial portion of its annual budget, specifically 17%, towards research and development efforts aimed at creating new products. It has two upcoming innovations. One is Soonyam that leverages biofeedback to offer users insights into their mind’s activity, making it an invaluable tool for meditation and psychological counseling. This innovative solution promotes improved mental health and a more balanced life. Second is Bone Conducting Hearing Aid that addresses specific hearing challenges that conventional devices cannot effectively manage. By conducting sound through bone, it provides an effective remedy for hearing loss that standard aids fall short in addressing.
